Aprea Therapeutics APRE 深 沪
已收盘 10-02 16:00:00 美东时间
0.695
-0.028
-3.94%
华盛通- 最 高0.7362
- 今 开0.716
- 成交量 86.23万股
- 最 低 0.685
- 昨 收 0.7235
- 总市值 875.08万
- 52周最高 1.69
- 市盈率 静 --
- 换手率 6.85%
- 52周最低 0.548
- 委 比 29.39%
- 总股本 1259.11万
- 历史最高 1062.20
- 量 比 2.08
- 振 幅 7.08%
- 历史最低 0.548
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics
Abstract accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain. "We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Sym...
09-22 20:33
Aprea Therapeutics Expands Current Patent Portfolio
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.
08-28 20:17
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Aprea Therapeutics, Inc. announced the expansion of its global intellectual property portfolio, with 28 issued and 30 pending patents. The company emphasized its commitment to innovation and leadership in precision medicine. Its WEE1 kinase inhibitor program includes 14 patent applications, while the ATR inhibitor program is protected by 31 granted patents and 14 pending applications. Both programs focus on proprietary compounds, compositions, an...
08-28 12:15
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
08-13 20:55
Aprea Therapeutics advances APR-1051 oncology pipeline progress
Aprea Therapeutics ( ($APRE) ) has shared an announcement. On August 12, 2026, ...
08-12 20:58
Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share from the same period last year.
08-12 20:32
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Aprea Therapeutics plans to report the next clinical data update for its Phase 1 ACESOT-1051 trial of APR-1051, an oral WEE1 inhibitor, at a medical meeting in Q4 2026. Enrollment is accelerating, with 6-10 patients expected per month by year-end. The company aims to expand APR-1051's development into uterine serous carcinoma, platinum-resistant ovarian cancer, and combination therapies for HPV-positive head and neck cancer and colorectal cancer....
07-30 12:00
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in June 2026
Short interest data from late June 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in speculative biotech plays like Rec...
07-01 22:20
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
06-01 20:08
